{"drugs":["Clofazimine","Lamprene"],"mono":{"0":{"id":"127735-s-0","title":"Generic Names","mono":"Clofazimine"},"1":{"id":"127735-s-1","title":"Dosing and Indications","sub":[{"id":"127735-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Erythema nodosum leprosum:<\/b> 100 to 200 mg ORALLY once a day for up to 3 months to facilitate corticosteroid dose reduction or elimination; taper dose to 100 mg as soon as reactive episode is controlled<\/li><li><b>Lepromatous leprosy:<\/b> (dapsone-sensitive multibacillary leprosy) 100 mg ORALLY once a day in combination with 2 other antileprosy drugs for at least 2 years; monotherapy can be instituted when negative skin smears are obtained<\/li><li><b>Lepromatous leprosy, Dapsone-resistant:<\/b> (dapsone-resistant leprosy) 100 mg ORALLY once a day in combination with 1 or more other antileprosy drugs for 3 years followed by monotherapy with 100 mg of clofazimine daily<\/li><\/ul>"},{"id":"127735-s-1-5","title":"Pediatric Dosing","mono":"Not approved by the US Food and Drug Administration for use in children"},{"id":"127735-s-1-6","title":"Dose Adjustments","mono":"<b>hepatic impairment:<\/b> severe hepatic insufficiency, consider dose adjustment; no specific recommendations available"},{"id":"127735-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Erythema nodosum leprosum<\/li><li>Lepromatous leprosy<\/li><li>Lepromatous leprosy, Dapsone-resistant<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Erythema dyschromicum perstans<\/li><li>Neuropathic ulcer<\/li><li>Pyoderma gangrenosum<\/li><li>Systemic lupus erythematosus<\/li><\/ul>"}]},"3":{"id":"127735-s-3","title":"Contraindications\/Warnings","sub":[{"id":"127735-s-3-9","title":"Contraindications","mono":"hypersensitivity to clofazimine products<br\/>"},{"id":"127735-s-3-10","title":"Precautions","mono":"<ul><li>history of gastrointestinal problems (abdominal pain, diarrhea)<\/li><li>pink to brownish-black skin discoloration; reversible but may take months to years<\/li><\/ul>"},{"id":"127735-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"127735-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Drugs for which the effect on nursing infants is unknown but may be of concern.<\/li><li>WHO: Compatible with breastfeeding.  Monitor infant for side effects.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"127735-s-4","title":"Drug Interactions","sub":{"1":{"id":"127735-s-4-14","title":"Major","mono":"<ul>Bedaquiline (theoretical)<\/ul>"},"2":{"id":"127735-s-4-15","title":"Moderate","mono":"<ul><li>Aluminum Hydroxide (established)<\/li><li>Fosphenytoin (probable)<\/li><li>Magnesium Hydroxide (established)<\/li><li>Phenytoin (probable)<\/li><\/ul>"}}},"5":{"id":"127735-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Congenital ichthyosis of skin (8% to 28%), Discoloration of skin (75% to 100%), Pruritus (1% to 5%.), Rash (1% to 5%.)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (40% to 50%.), Diarrhea (40% to 50%.), Epigastric pain (40% to 50%.), Nausea (40% to 50%.), Vomiting (40% to 50%.)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythroderma (less than 1%)<\/li><li><b>Gastrointestinal:<\/b>Bowel obstruction (less than 1%), Disorder of intestine, Gastrointestinal hemorrhage (less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatitis (less than 1%)<\/li><li><b>Psychiatric:<\/b>Reactive depression (situational), Due to skin discoloration<\/li><li><b>Other:<\/b>Splenic infarction<\/li><\/ul>"},"6":{"id":"127735-s-6","title":"Drug Name Info","sub":{"0":{"id":"127735-s-6-17","title":"US Trade Names","mono":"Lamprene<br\/>"},"2":{"id":"127735-s-6-19","title":"Class","mono":"Leprostatic<br\/>"},"3":{"id":"127735-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"127735-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"127735-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Exact mechanism unknown; has a slowly bactericidal effect on  Mycobacterium leprae; inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. <\/li><li>Exerts anti-inflammatory effects in the control of erythema nodosum leprosum reactions. <\/li><\/ul>"},"8":{"id":"127735-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"127735-s-8-23","title":"Absorption","mono":"Systemic: Variable; Bioavailability: 70%; food increases absorption <br\/>"},"3":{"id":"127735-s-8-26","title":"Excretion","mono":"Systemic: Fecal\/biliary: up to 50% unchanged; Renal: 1% unchanged and 0.6% metabolites; Sputum\/sebum\/sweat: small amounts <br\/>"},"4":{"id":"127735-s-8-27","title":"Elimination Half Life","mono":"Systemic: 70 d <br\/>"}}},"9":{"id":"127735-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take with meals <br\/>"},"10":{"id":"127735-s-10","title":"Monitoring","mono":"<ul><li>reduction in arthralgias, fever, leukocytosis, neuritis, and skin lesions<\/li><li>signs and symptoms of depression<\/li><li>signs and symptoms of gastrointestinal problems<\/li><\/ul>"},"11":{"id":"127735-s-11","title":"How Supplied","mono":"<b>Lamprene<\/b><br\/>Oral Capsule: 50 MG<br\/>"},"13":{"id":"127735-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that drug may cause red to brownish-black discoloration of skin. This effect is reversible, but may take months or years to return to normal.<\/li><li>This drug may also cause red or brownish-black discoloration of conjunctivae, body fluids, or feces.<\/li><li>This drug may cause dry skin.<\/li><li>Instruct patient to report signs\/symptoms of depression (secondary to skin discoloration) or gastrointestinal problems (nausea, vomiting, bowel obstruction, gastrointestinal hemorrhage).<\/li><li>Patient should take drug with meals.<\/li><\/ul>"}}}